INDEX Italicised numbers indicate tables 2-phenoxyethanol, in vaccines, 19, 484 7vPCV (7-valent pneumococcal conjugate vaccine), 45, 56–60, 108, 194, 320, 321, 322, 328, 333 adverse events following immunisation (AEFI), 335 pneumococcal disease epidemiology, 318–319 10vPCV (10-valent pneumococcal conjugate vaccine), 8, 14, 43, 46, 52–53, 56, 58, 60, 68, 194, 319, 320. see also pneumococcal disease adverse events following immunisation (AEFI), 335 dosage and administration, 323–324 and Indigenous children, 108 pregnancy and breastfeeding, 334 route of vaccine administration, 68–69 transport, storage and handling, 323 vaccination recommendations, 324–333 13vPCV (13-valent pneumococcal conjugate vaccine), 8, 14–15, 43, 46, 62, 68, 105, 149, 151, 156, 160, 160–161, 163–164, 174, 194, 251, 257, 319–322 adverse events following immunisation (AEFI), 334–335 catch-up vaccination, 52–53, 57–58 catch-up vaccination guidelines for children with medical condition associated with an increased risk, 59–60 catch-up vaccination guidelines for children without medical condition associated with an increased risk, 56 catch-up vaccination schedules for those ≥10 years of age, 63–64 dosage and administration, 323–324 and Indigenous children, 108 and influenza vaccination, 257 minimum acceptable vaccine dose intervals, 50 number of vaccine doses for children, 49 precautions, 334 pregnancy and breastfeeding, 136, 334 vaccination recommendations, 324–333 variations from product information, 336–337 23vPPV (23-valent pneumococcal polysaccharide vaccine), 15, 62, 105, 110, 137, 143, 149, 151, 156, 160, 161, 163, 163–164, 321, 321–322, 455, 471 adverse events following immunisation (AEFI), 336 catch-up vaccination guidelines for children with medical condition associated with an increased risk, 59–60 500 <strong>The</strong> <strong>Australian</strong> <strong>Immunisation</strong> <strong>Handbook</strong> <strong>10th</strong> edition catch-up vaccination schedules for those ≥10 years of age, 63–64 minimum acceptable vaccine dose intervals, 50 number of vaccine doses for children, 49 pneumococcal disease epidemiology, 318–319 route of vaccine administration, 68–69 vaccination recommendations, 324–333 A abattoir workers. see animals, persons working with abbreviations list, 495–497 Aboriginal and Torres Strait Islander people, 35, 104–112 additional recommended vaccines, 105 adults, 109–111 catch-up vaccination, 57–58 changes to recommendations in the <strong>10th</strong> edition of the handbook, 9, 12, 15 children, 49, 50, 106–108 Haemophilus influenzae type b (Hib), 106–107, 192 hepatitis A, 47, 107, 198–199, 201, 203, 206 hepatitis B, 109, 209, 221 human papillomavirus (HPV), 233 influenza, 108, 109–110, 246, 254 Japanese encephalitis, 111 pneumococcal disease, 52–53, 108, 110–111, 133, 318–319, 321, 324–325, 327–328, 329, 330–332 rotavirus, 373 rubella, 111, 390 service delivery to, 112 tuberculosis, 106, 408, 412 Act-HIB, 51, 55, 192 transport, storage and handling, 194 variations from product information, 197 active immunisation, 18–20 acute febrile illness, vaccination recommendations, 31 acute otitis media (AOM). see otitis media acute systemic illness, vaccination recommendations, 31 Adacel, 123, 185, 306, 400 vaccine components, 470–471 variations from product information, 189, 315, 406–407 Adacel Polio, 185, 189, 306, 315, 340, 344, 400 variations from product information, 407 additives, in vaccines, 485–486 adjuvants, in vaccines, 19, 484–485 administration of vaccines, 65–84 changes in the <strong>10th</strong> edition of the handbook, 9 equipment, 65–69
identifying the injection site, 79–82 injection techniques, 71–73 multiple vaccine injections, 83–84 occupational health and safety issues, 65 positioning, 75–78 preparation, 70 recommended injection sites, 73–74 route, 67–69 adolescents catch-up vaccination schedules, 61–62, 63–64 diphtheria, 186 hepatitis B, 213, 214, 214–215, 220 human papillomavirus (HPV), 238 injection sites, 74 measles, post-exposure prophylaxis, 281 measles, vaccination, 273 multiple vaccine injections, 83–84 mumps, 299–300 pertussis, 306 positioning for vaccination, 78 Q fever, 348–350 rabies, 356–357 rubella, 389–390 tetanus, 400, 401 varicella, 425, 428–429, 429 adrenaline autoinjectors, 90–91 doses, 90 in management of anaphylaxis, 89–91 ADT Booster, 123, 184, 400 variations from product information, 189, 406 adults catch-up vaccination schedules, 61–64, 63–64 cholera, 179 consent on behalf of an adult lacking capacity, 27 diphtheria, 186–187 hepatitis A, 202 hepatitis B, 213–214, 214–215, 220–224 human papillomavirus (HPV), 238–239 Indigenous persons, 109–111 influenza, 251 injection sites, 74 measles, post-exposure prophylaxis, 281 measles, vaccination, 273 multiple vaccine injections, 83–84 mumps, 299–300 pertussis, 306, 308–309 pneumococcal disease, 326–327, 330–333 poliomyelitis, 342 positioning for vaccination, 78 Q fever, 348–350 rabies, 356–357 rubella, 389–390 tetanus, 400, 402, 403–404 vaccination status and history, 40 varicella vaccination, 425, 429 and varicella vaccination, 434 yellow fever vaccination, 444 and zoster, 446–447, 447–448 zoster vaccination, 450–453 adverse events following immunisation (AEFI), 9, 18, 21–23, 85–97, 481–482 anaphylaxis and vasovagal episodes, 87–91 cholera, 181 common events, 91 diphtheria, 187–188 events without causal link, 94 Haemophilus influenzae type b (Hib), 196 hepatitis A, 207 hepatitis B, 227–228 human papillomavirus (HPV), 240, 241–242 influenza, 249, 257–258 Japanese encephalitis, 265–266 measles, 278–280 meningococcal disease, 292 mumps, 301 mumps vaccination, 301 passive immunisation, 458, 464 pertussis, 311, 312–313 pneumococcal disease, 335–336 poliomyelitis, 343 poliomyelitis vaccination, 343 Q fever, 351–352 rabies and other lyssaviruses (including <strong>Australian</strong> bat lyssavirus), 370–371 reporting of, 94–97 rotavirus, 381–382 rubella, 394 state and territory contact information, 96 tetanus, 405 tuberculosis (TB), 414 typhoid, 422 uncommon or rare events, 92–93 vaccination of persons who have had an AEFI, 130–133 varicella, 433–435 yellow fever, 443, 444–445 zoster (herpes zoster), 448, 454 Aedes aegypti, 439. see also yellow fever Africa cholera, 176 hepatitis B, 118, 209, 221 influenza, 245 measles, 268, 269 meningococcal disease, 120, 284 migrants to Australia from, 174 poliomyelitis, 338 rabies and other lyssaviruses (including <strong>Australian</strong> bat lyssavirus), 354, 361 rubella, 390 INDEX 501 INDEX
- Page 1 and 2:
The Australian Immunisation Handboo
- Page 3 and 4:
FOREWORD Since 1932, when Governmen
- Page 5 and 6:
TABLE OF CONTENTS PART 1 INTRODUCTI
- Page 7 and 8:
LIST OF TABLES Table 2.1.1: Pre-vac
- Page 9 and 10:
List 4.13.1: Conditions associated
- Page 11 and 12:
PREFACE The 10th edition of The Aus
- Page 13 and 14:
Secretariat support, Australian Tec
- Page 15 and 16:
PART 1 INTRODUCTION TO THE AUSTRALI
- Page 17 and 18:
1.2 DEVELOPMENT OF THE 10TH EDITION
- Page 19 and 20:
1.3 HOW TO USE THE 10TH EDITION HAN
- Page 21 and 22:
1.4 WHAT’S NEW All chapters have
- Page 23 and 24:
2.2 Administration of vaccines •
- Page 25 and 26:
• The section on vaccination of p
- Page 27 and 28:
4.6 Human papillomavirus • HPV va
- Page 29 and 30:
• For Aboriginal and Torres Strai
- Page 31 and 32:
Part 5 Passive immunisation • Inf
- Page 33 and 34:
without the harmful consequences of
- Page 35 and 36:
(vaccine failure). Often such infec
- Page 37 and 38:
will occur following receipt of a s
- Page 39 and 40:
cases, both the doctor issuing the
- Page 41 and 42:
Should a child or adolescent refuse
- Page 43 and 44:
• check that the correct time int
- Page 45 and 46:
Note: Please discuss this informati
- Page 47 and 48:
Condition or circumstance of person
- Page 49 and 50:
Condition or circumstance of person
- Page 51 and 52:
Table 2.1.3: Live attenuated parent
- Page 53 and 54:
An online ‘catch-up calculator’
- Page 55 and 56:
Use of serological testing to guide
- Page 57 and 58:
• For some vaccines, catch-up vac
- Page 59 and 60:
Figure 2.1.1: Catch-up worksheet fo
- Page 61 and 62:
Vaccine Minimum age for 1st dose in
- Page 63 and 64:
Table 2.1.6: Number of vaccine dose
- Page 65 and 66:
Catch-up guidelines for individual
- Page 67 and 68:
If 13vPCV is not available, and 10v
- Page 69 and 70:
Previous vaccination history 2 prev
- Page 71 and 72:
PART 2 VACCINATION PROCEDURES 57 Ta
- Page 73 and 74:
PART 2 VACCINATION PROCEDURES 59 Ta
- Page 75 and 76:
Catch-up schedules for persons ≥1
- Page 77 and 78:
For additional details on these rec
- Page 79 and 80:
2.2 ADMINISTRATION OF VACCINES 2.2.
- Page 81 and 82:
• Never freeze a vaccine after it
- Page 83 and 84:
PART 2 VACCINATION PROCEDURES 69 In
- Page 85 and 86:
2.2.5 Vaccine injection techniques
- Page 87 and 88:
Interruption to a vaccination If th
- Page 89 and 90:
2.2.7 Positioning for vaccination I
- Page 91 and 92:
Children ≥12 months of age Cuddle
- Page 93 and 94:
2.2.8 Identifying the injection sit
- Page 95 and 96:
• Place the palm over the greater
- Page 97 and 98:
2.2.9 Administering multiple vaccin
- Page 99 and 100:
2.3 POST-VACCINATION 2.3.1 Immediat
- Page 101 and 102:
Management of an immediate adverse
- Page 103 and 104:
Management of anaphylaxis Rapid IM
- Page 105 and 106:
Autoinjectors are generally not app
- Page 107 and 108:
Australia. 16 This vaccine is no lo
- Page 109 and 110:
Any serious or unexpected adverse e
- Page 111 and 112:
Consumers and immunisation service
- Page 113 and 114:
When relevant, immunisation service
- Page 115 and 116:
National Human Papillomavirus Vacci
- Page 117 and 118:
Immunisation service providers enro
- Page 119 and 120:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 121 and 122:
Thus, a vaccine to prevent Hib dise
- Page 123 and 124:
3.1.2 Adults Hepatitis B Indigenous
- Page 125 and 126:
een low in younger Indigenous adult
- Page 127 and 128:
3.2 VACCINATION FOR INTERNATIONAL T
- Page 129 and 130:
• vaccination history (including
- Page 131 and 132:
departure to allow for the period w
- Page 133 and 134:
Selected vaccines based on travel i
- Page 135 and 136:
Tick-borne encephalitis Tick-borne
- Page 137 and 138:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 139 and 140:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 141 and 142:
3.2.5 Vaccinating the traveller wit
- Page 143 and 144:
• Travel health and quarantine se
- Page 145 and 146:
whether the AEFI is likely to recur
- Page 147 and 148:
(see Appendix 1 Contact details for
- Page 149 and 150:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 151 and 152:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 153 and 154:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 155 and 156:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 157 and 158:
avoided, except in situations where
- Page 159 and 160:
3.3.3 Vaccination of immunocompromi
- Page 161 and 162:
Use of live viral or live bacterial
- Page 163 and 164:
Influenza vaccination is recommende
- Page 165 and 166:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 167 and 168:
PART 3 VACCINATION FOR SPECIAL RISK
- Page 169 and 170:
Haematopoietic stem cell transplant
- Page 171 and 172:
Vaccine Months after HSCT Comments
- Page 173 and 174:
depending on the number of vaccines
- Page 175 and 176:
Persons with functional or anatomic
- Page 177 and 178:
Table 3.3.5: Recommendations for va
- Page 179 and 180:
Persons with autoimmune diseases an
- Page 181 and 182:
Table 3.3.6: Recommended intervals
- Page 183 and 184:
3.3.7 Vaccination of persons at occ
- Page 185 and 186:
Occupation Vaccine Providers of hom
- Page 187 and 188:
against certain vaccine-preventable
- Page 189 and 190:
3.3.11 Vaccination of persons who i
- Page 191 and 192:
waters. All cases of cholera report
- Page 193 and 194:
Children aged 2-6 years Three doses
- Page 195 and 196:
4.1.11 Adverse events The inactivat
- Page 197 and 198:
4.2.4 Vaccines Diphtheria toxoid is
- Page 199 and 200:
• Adacel - Sanofi Pasteur Pty Ltd
- Page 201 and 202:
antibodies at an age when waning of
- Page 203 and 204:
children aged
- Page 205 and 206:
4.3 HAEMOPHILUS INFLUENZAE TYPE B 4
- Page 207 and 208:
• Hiberix - GlaxoSmithKline (PRP-
- Page 209 and 210:
4.3.7 Recommendations Infants A Hib
- Page 211 and 212:
4.3.11 Public health management of
- Page 213 and 214:
In recent years, hepatitis A notifi
- Page 215 and 216:
Inactivated hepatitis A vaccines ar
- Page 217 and 218:
Co-administration with other vaccin
- Page 219 and 220:
Recommendations for the use of comb
- Page 221 and 222:
4.4.10 Adverse events The most comm
- Page 223 and 224:
4.5.3 Epidemiology The prevalence o
- Page 225 and 226:
4.5.4 Vaccines Monovalent hepatitis
- Page 227 and 228:
For older children and young adults
- Page 229 and 230:
Vaccine Age of vaccine recipient Do
- Page 231 and 232:
Combination hepatitis A/hepatitis B
- Page 233 and 234:
Management of infants born to mothe
- Page 235 and 236:
Household or other close (household
- Page 237 and 238:
with occult hepatitis B infection.
- Page 239 and 240:
immune memory persists and is thoug
- Page 241 and 242:
to suggest that a higher proportion
- Page 243 and 244:
Table 4.5.3: Post-exposure prophyla
- Page 245 and 246:
4.6 HUMAN PAPILLOMAVIRUS 4.6.1 Viro
- Page 247 and 248:
women. The prevalence of high-risk
- Page 249 and 250:
• Gardasil - CSL Limited/Merck &
- Page 251 and 252:
If scheduled doses have been missed
- Page 253 and 254:
However, some adult males may gain
- Page 255 and 256:
4.6.9 Contraindications The only ab
- Page 257 and 258:
4.7 INFLUENZA 4.7.1 Virology The in
- Page 259 and 260:
Figure 4.7.1: Influenza notificatio
- Page 261 and 262:
Always check annual seasonal influe
- Page 263 and 264:
7.5 µg of viral haemagglutinin (in
- Page 265 and 266:
Table 4.7.1: Recommended doses of i
- Page 267 and 268:
• Chronic respiratory conditions,
- Page 269 and 270:
Residents of residential aged care
- Page 271 and 272:
influenza vaccine prior to administ
- Page 273 and 274:
4.8 JAPANESE ENCEPHALITIS 4.8.1 Vir
- Page 275 and 276:
28 days following vaccination with
- Page 277 and 278:
When using JEspect in children aged
- Page 279 and 280:
4.8.8 Pregnancy and breastfeeding I
- Page 281 and 282:
4.9 MEASLES 4.9.1 Virology Measles
- Page 283 and 284:
4.9.4 Vaccines Monovalent measles v
- Page 285 and 286:
4.9.6 Dosage and administration The
- Page 287 and 288:
Table 4.9.1: Recommendations for me
- Page 289 and 290:
increase in adverse events from vac
- Page 291 and 292:
Immunoglobulin or blood product adm
- Page 293 and 294:
approximately 5%. 2,25 There is als
- Page 295 and 296:
Table 4.9.2: Post-exposure prophyla
- Page 297 and 298:
4.10 MENINGOCOCCAL DISEASE 4.10.1 B
- Page 299 and 300:
4.10.4 Vaccines There are different
- Page 301 and 302:
Polysaccharide vaccines Quadrivalen
- Page 303 and 304:
Interchangeability of meningococcal
- Page 305 and 306:
• Children (aged ≥9 months) and
- Page 307 and 308:
Appendix 1 Contact details for Aust
- Page 309 and 310:
4.11 MUMPS 4.11.1 Virology Mumps is
- Page 311 and 312:
Trivalent measles-mumps-rubella (MM
- Page 313 and 314:
4.11.7 Recommendations Infants aged
- Page 315 and 316:
Vaccination with other live attenua
- Page 317 and 318:
acquired from healthcare workers. 1
- Page 319 and 320:
demonstrated a more rapid decline,
- Page 321 and 322:
• Boostrix-IPV - GlaxoSmithKline
- Page 323 and 324:
in the previous 10 years. 19,45 Adu
- Page 325 and 326:
(see ‘Women who are planning preg
- Page 327 and 328:
an HHE. An HHE may last from a few
- Page 329 and 330:
The product information for Quadrac
- Page 331 and 332:
4.13 PNEUMOCOCCAL DISEASE 4.13.1 Ba
- Page 333 and 334:
non-Indigenous children (88%). 19,2
- Page 335 and 336:
10-valent pneumococcal conjugate va
- Page 337 and 338:
lesser antibody responses to 2nd or
- Page 339 and 340:
Table 4.13.1: Recommendations for p
- Page 341 and 342:
Category B: Conditions associated w
- Page 343 and 344:
Children aged >5 years to 15 years)
- Page 345 and 346:
Non-Indigenous adults A single dose
- Page 347 and 348:
Adults who have a condition listed
- Page 349 and 350:
4.13.11 Adverse events 10-valent pn
- Page 351 and 352:
5 years with a condition(s) associa
- Page 353 and 354:
virtually eradicated in India, but
- Page 355 and 356:
formaldehyde, glutaraldehyde, polys
- Page 357 and 358:
4.14.8 Pregnancy and breastfeeding
- Page 359 and 360:
4.15 Q FEVER 4.15.1 Bacteriology Q
- Page 361 and 362:
4.15.4 Vaccine • Q-Vax - CSL Limi
- Page 363 and 364:
individuals, which can be accessed
- Page 365 and 366:
Refer to 3.3 Groups with special va
- Page 367 and 368:
4.16 RABIES AND OTHER LYSSAVIRUSES
- Page 369 and 370:
4.16.4 Rabies vaccines • Mérieux
- Page 371 and 372:
of an even more accelerated schedul
- Page 373 and 374:
Pre-exposure prophylaxis for rabies
- Page 375 and 376:
The relevant state/territory health
- Page 377 and 378:
Although data are limited on the ef
- Page 379 and 380:
Table 4.16.2: Post-exposure prophyl
- Page 381 and 382:
Figure 4.16.2: Post-exposure prophy
- Page 383 and 384:
Figure 4.16.3: Booster algorithm fo
- Page 385 and 386:
allergic reaction occurs following
- Page 387 and 388:
age group11,12 and affecting 3.8% o
- Page 389 and 390:
of age, the risk of IS was increase
- Page 391 and 392:
Interchangeability of rotavirus vac
- Page 393 and 394:
gestational age; median 34 weeks) w
- Page 395 and 396:
Infants living in households with p
- Page 397 and 398:
4.17.12 Variations from product inf
- Page 399 and 400:
2003, rubella notifications in Aust
- Page 401 and 402:
zoster virus [Oka strain]). Lyophil
- Page 403 and 404:
children
- Page 405 and 406:
A number of commercial assays for t
- Page 407 and 408:
Germany indicates that no case of v
- Page 409 and 410:
case. Seronegative women of child-b
- Page 411 and 412:
4.19 TETANUS 4.19.1 Bacteriology Te
- Page 413 and 414:
Formulations for children aged
- Page 415 and 416:
4.19.5 Transport, storage and handl
- Page 417 and 418:
foreign bodies (especially wood spl
- Page 419 and 420:
studies indicate that the adverse r
- Page 421 and 422:
The product information for Adacel
- Page 423 and 424:
of MDR-TB cases identified has incr
- Page 425 and 426:
BCG vaccination procedures BCG vacc
- Page 427 and 428:
Occupational groups There is some e
- Page 429 and 430:
4.20.13 Variations from product inf
- Page 431 and 432:
In developed countries, typhoid fev
- Page 433 and 434:
A 4th capsule taken on day 7 has be
- Page 435 and 436:
4.21.8 Pregnancy and breastfeeding
- Page 437 and 438:
4.22 VARICELLA 4.22.1 Virology Vari
- Page 439 and 440:
as a case of wild-type varicella oc
- Page 441 and 442:
Reconstituted Varivax Refrigerated
- Page 443 and 444:
adequate protection from varicella.
- Page 445 and 446:
eceived varicella vaccine while bre
- Page 447 and 448:
immunoglobulin and other blood prod
- Page 449 and 450:
eported in a 9-year follow-up of 70
- Page 451 and 452:
high-dose intravenous NHIG are like
- Page 453 and 454:
4.23 YELLOW FEVER 4.23.1 Virology Y
- Page 455 and 456:
Co-administration with other vaccin
- Page 457 and 458:
4.23.8 Pregnancy and breastfeeding
- Page 459 and 460:
Vaccine-associated neurotropic adve
- Page 461 and 462:
1000 cases per 100 000 population i
- Page 463 and 464: administration of Zostavax with 23-
- Page 465 and 466: diagnosis. In addition, the risk of
- Page 467 and 468: Laboratory testing to check for an
- Page 469 and 470: 4.24.12 Variations from product inf
- Page 471 and 472: the immunoglobulin preparations con
- Page 473 and 474: Prevention of measles Measles vacci
- Page 475 and 476: who are being treated with immunosu
- Page 477 and 478: limb with a separate syringe, and a
- Page 479 and 480: APPENDIX 1: CONTACT DETAILS FOR AUS
- Page 481 and 482: APPENDIX 2: LITERATURE SEARCH STRAT
- Page 483 and 484: APPENDIX 3: COMPONENTS OF VACCINES
- Page 485 and 486: Vaccine component* Vaccine brand
- Page 487 and 488: APPENDIX 4: COMMONLY ASKED QUESTION
- Page 489 and 490: When should preterm infants be vacc
- Page 491 and 492: If a parent decides not to have a c
- Page 493 and 494: Should vaccines be given to persons
- Page 495 and 496: eason not to vaccinate. Asthma, ecz
- Page 497 and 498: Does MMR vaccine cause inflammatory
- Page 499 and 500: (either alone or in combination) fo
- Page 501 and 502: A4.5 Questions about the need for i
- Page 503 and 504: APPENDIX 5: GLOSSARY OF TECHNICAL T
- Page 505 and 506: Enzootic enzootic infections are pr
- Page 507 and 508: Rotavirus a virus that is a common
- Page 509 and 510: APPENDIX 6: COMMONLY USED ABBREVIAT
- Page 511 and 512: OPV oral poliomyelitis vaccine PCEC
- Page 513: Year Vaccine 2003 Varicella 2003 Me
- Page 517 and 518: Australian Capital Territory advers
- Page 519 and 520: and travellers, 119 vaccines, 177-1
- Page 521 and 522: abies and other lyssaviruses (inclu
- Page 523 and 524: HPV Vaccination Program, 234 human
- Page 525 and 526: interferon-gamma release assays (IG
- Page 527 and 528: mercury, in vaccines. see thiomersa
- Page 529 and 530: Northern Territory ACIR reporting,
- Page 531 and 532: and Haemophilus influenzae type b (
- Page 533 and 534: espiratory syncytial virus monoclon
- Page 535 and 536: Therapeutic Goods Administration (T
- Page 537 and 538: varicella-zoster immunoglobulin, 45
- Page 539 and 540: INDEX 525 INDEX